HER2-mutant Non-Small Cell Lung Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight, 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in HER2-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the HER2-mutant Non-Small Cell Lung Cancer Pipeline Report
• DelveInsight's HER2-mutant Non-Small Cell Lung Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for HER2-mutant Non-Small Cell Lung Cancer treatment.
• The leading companies working in the HER2-mutant Non-Small Cell Lung Cancer Market include Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, Spectrum Pharmaceuticals Inc. and others.
• Promising HER2-mutant Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include Trastuzumab deruxtecan, ELVN-002, Trastuzumab emtansine, Neratinib, Temsirolimus, DZD9008, and others.
• March 2024:- Enliven Therapeutics- The goal of this clinical trial is to test ELVN-002 in people with cancers that have an abnormal HER2 gene. The main question the trial aims to answer is if ELVN-002 is safe and tolerable at different doses. A second main question is to evaluate the concentration of ELVN-002 in the blood at different doses and to see how this correlates with safety and see how the concentration of drug changes over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-small cell lung cancer.

To explore more information on the latest breakthroughs in the HER2-mutant Non-Small Cell Lung Cancer treatment landscape of the report, click here @ HER2-mutant Non-Small Cell Lung Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/her2-mutant-non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HER2-mutant Non-Small Cell Lung Cancer Overview
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers. NSCLC is one of the most genomically diverse cancers, making it very difficult to treat. For all NSCLC patients who have the adenocarcinoma subtype, testing for alterations in epidermal growth factor receptor (EGFR), mesenchymal epithelial transition factor (MET), b-raf proto-oncogene (BRAF), anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), ret proto-oncogene (RET) and neurotrophic tyrosine receptor kinase (NTRK) is recommended by the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) guidelines.

HER2-mutant Non-Small Cell Lung Cancer Emerging Drugs Profile

• DZD-9008: Dizal Pharmaceuticals
DZD9008 is a selective, irreversible EGFR inhibitor, which is currently being evaluated for the treatment of both EGFRexon20 insertion mutation-positive NSCLC and HER2-mutated NSCLC. In the open-label, multicenter phase I/II study (NCT03974022), 220 patients with EGFRexon20 insertion mutation-positive or HER2-positive NSCLC were treated with DZD9008 at doses of 50 mg to 400 mg once daily.

• Enhertu: AstraZeneca
Enhertu is a HER2-directed ADC. Designed using Daiichi Sankyo's proprietary DXd ADC technology, Enhertu is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced programme in AstraZeneca's ADC scientific platform. Enhertu consists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker. Enhertu (5.4mg/kg) is approved in more than 40 countries for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens based on the results from the DESTINY-Breast01 trial. Enhertu (6.4mg/kg) is approved in several countries for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastro esophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 trial.

• Pyrotinib: Jiangsu Hengrui Medicine
Pyrotinib is a novel irreversible and selective EGFR/HER2 tyrosine kinase inhibitor developed by Hengrui. In 2018, pyrotinib was approved in China in combination with capecitabine for the treatment of relapsed or metastatic HER2-positive breast cancer. Currently, two Phase III studies are ongoing to evaluate pyrotinib as 1st-line treatment (NCT03863223) and extended adjuvant treatment (NCT03980054), respectively in HER2-positive breast cancer patients. In addition to breast cancer, pyrotinib demonstrated superior clinical benefits in advanced non-small cell lung cancer (NSCLC) with HER2 exon 20 mutation in a Phase II study. A global Phase III study (NCT04447118) is ongoing to investigate pyrotinib in patients with advanced non-squamous NSCLC with HER2 exon 20 mutation who previously failed platinum-based chemotherapy.

For further information, refer to the detailed HER2-mutant Non-Small Cell Lung Cancer Unmet Needs, HER2-mutant Non-Small Cell Lung Cancer Market Drivers, and HER2-mutant Non-Small Cell Lung Cancer Market Barriers, click here for HER2-mutant Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/her2-mutant-non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HER2-mutant Non-Small Cell Lung Cancer Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for HER2-mutant Non-Small Cell Lung Cancer. The companies which have their HER2-mutant Non-Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. Preregistration include, AstraZeneca.

DelveInsight's HER2-mutant Non-Small Cell Lung Cancer pipeline report covers around 5+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Request a sample and discover the recent advances in HER2-mutant Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, click here @ HER2-mutant Non-Small Cell Lung Cancer Treatment Landscape- https://www.delveinsight.com/sample-request/her2-mutant-non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HER2-mutant Non-Small Cell Lung Cancer Companies
Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, Spectrum Pharmaceuticals Inc. and others.

HER2-mutant Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

HER2-mutant Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Dive deep into rich insights for drugs for HER2-mutant Non-Small Cell Lung Cancer Pipeline, click here @ HER2-mutant Non-Small Cell Lung Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/her2-mutant-non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the HER2-mutant Non-Small Cell Lung Cancer Pipeline Report
• Coverage- Global
• HER2-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HER2-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• HER2-mutant Non-Small Cell Lung Cancer Companies- Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, Spectrum Pharmaceuticals Inc. and others.
• HER2-mutant Non-Small Cell Lung Cancer Pipeline Therapies- Trastuzumab deruxtecan, ELVN-002, Trastuzumab emtansine, Neratinib, Temsirolimus, DZD9008, and others.

Got Queries? Find out the related information on HER2-mutant Non-Small Cell Lung Cancer Mergers and acquisitions, HER2-mutant Non-Small Cell Lung Cancer Licensing Activities @ HER2-mutant Non-Small Cell Lung Cancer Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/her2-mutant-non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. HER2-mutant Non-Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HER2-mutant Non-Small Cell Lung Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. Enhertu: AstraZeneca
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. DZD-9008: Dizal Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name : Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. HER2-mutant Non-Small Cell Lung Cancer Key Companies
21. HER2-mutant Non-Small Cell Lung Cancer Key Products
22. HER2-mutant Non-Small Cell Lung Cancer- Unmet Needs
23. HER2-mutant Non-Small Cell Lung Cancer- Market Drivers and Barriers
24. HER2-mutant Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
25. HER2-mutant Non-Small Cell Lung Cancer Analyst Views
26. HER2-mutant Non-Small Cell Lung Cancer Key Companies
27. Appendix

List of Important Links-

https://www.wowonder.xyz/read-blog/65223
https://diccut.com/germandennydones
https://us.newyorktimesnow.com/dennydones9193
https://www.mymeetbook.com/germanydennydones
https://wiwonder.com/1716272393254738_2674
https://www.japanesewomenorg.com/read-blog/15585
https://tannda.net/read-blog/62770
https://evahno.com/read-blog/22402
https://www.pickmemo.com/read-blog/307268
https://ai.ceo/read-blog/132421
https://www.truthsocialviet.com/read-blog/58205
https://hanzuzhisheng.com/read-blog/489
https://www.testimonyforgod.com/read-blog/3019
https://www.skillsire.com/germandennydones
https://meetplayer.com/8a48fed02
https://zekond.com/read-blog/37531
https://shareyoursocial.com/germanydennydones
https://www.snipesocial.co.uk/dennydones9911
https://social.studentb.eu/read-blog/182065

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.